Lumexa Imaging Holdings Inc Revenue Growth Rates (LMRI), Current and Historic Growth - CSIMarket
CSIMarket
 


Lumexa Imaging Holdings Inc   (LMRI)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

LMRI's Revenue Growth by Quarter and Year

Lumexa Imaging Holdings Inc 's Revenue results by quarter and year




LMRI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 264.16
1st Quarter March 252.54
FY 516.70





LMRI Revenue second quarter 2026 Y/Y Growth Comment
Lumexa Imaging Holdings Inc in the second quarter 2026 achieved Revenue of $ 264.16 millions compare to recorded in same quarter a year ago.

Looking into second quarter 2026 results within Medical Laboratories industry 10 other companies have achieved higher Revenue growth. While Lumexa Imaging Holdings Inc ' s Revenue no change of 0% ranks overall at the positon no. 1167 in the second quarter 2026.




LMRI Revenue ( Y/Y Growth %) 2026
2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Lumexa Imaging Holdings Inc 's second quarter 2026 Revenue $ 264.16 millions LMRI's Income Statement
Lumexa Imaging Holdings Inc 's second quarter 2025 Revenue $ 0.00 millions Quarterly LMRI's Income Statement


LMRI Revenue (Quarter on Quarter Growth %)

2026
2025 2024 2023
4th Quarter December - 2.61 % - -
3rd Quarter September - - - -
2nd Quarter June 4.6 % - - -
1st Quarter March 0.45 % - - -
FY (Year on Year)   - - - -




Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #11
Healthcare Sector #175
Overall #1167

Revenue Y/Y Growth Statistics
High Average Low
4.6 % 3.61 % 2.61 %
(Jun 30 2026)   (Jun 30 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #11
Healthcare Sector #175
Overall #1167
Revenue Y/Y Growth Statistics
High Average Low
4.6 % 3.61 % 2.61 %
(Jun 30 2026)   (Jun 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Lumexa Imaging Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4.6 % 3.61 % 2.61 %
(Jun 30 2026)  


LMRI's II. Quarter Q/Q Revenue Comment
Lumexa Imaging Holdings Inc achieved in the II. Quarter 2026 above company average sequential Revenue growth of 4.6%, to $ 264.16 millions, from $252.54 millions in the first quarter.
LMRI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Lumexa Imaging Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1167.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #11
Healthcare Sector #175
Overall #1167
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #11
Healthcare Sector #175
Overall #1167
Revenue Q/Q Growth Statistics
High Average Low
4.6 % 3.61 % 2.61 %
(Jun 30 2026)  


LMRI's II. Quarter Q/Q Revenue Comment
Lumexa Imaging Holdings Inc achieved in the II. Quarter 2026 above company average sequential Revenue growth of 4.6%, to $ 264.16 millions, from $252.54 millions in the first quarter.
LMRI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Lumexa Imaging Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1167.


Lumexa Imaging Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)
12 Months Ending
12 Months Ending
12 Months Ending
12 Months Ending
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Mar 31 2026 period, Lumexa Imaging Holdings Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Lumexa Imaging Holdings Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Mar 31 2026 period, Lumexa Imaging Holdings Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Lumexa Imaging Holdings Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LMRI's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Lumexa Imaging Holdings Inc Revenue Growth Rates (LMRI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lumexa Imaging Holdings Inc (CIK 2071288).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-348902
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lumexa Imaging Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.